Affiliation:
1. The Department of Scientific Education The First People's Hospital of Jiande Jiande Hangzhou Zhejiang China
2. Institute of Regenerative Biology and Medicine, Helmholtz Center Munich Munich Germany
Abstract
AbstractBackgroundCutaneous angiosarcoma (cAS) is a rare and not well‐established malignant neoplasm characterized by dismal prognosis. Treatment for cAS remains controversial.ObjectiveFrom 1975 to 2016, a total of 872 patients with cAS (379 secondary cAS [s‐cAS] patients and 493 de novo cAS [dn‐cAS]) patients were identified from the Surveillance, Epidemiology, and End Results (SEER) database.MethodsSurvival analyses were performed utilizing Kaplan‐Meier curves and Cox proportional hazards regression models.ResultsBoth the number of s‐cAS patients and dn‐cAS patients climbed steadily over 42 years. There is a gradual increase in the proportion of s‐cAS among whole cAS patients for each interval, ranging from 0% to 51.2%.Taking into account a combination of Kaplan‐Meier and Cox regression methods, the survival of s‐cAS is similar to dn‐cAS. On multivariate analysis, older age, greater tumor size, primary site located at lower extremity, advanced stage, and no surgery were independent prognostic factors of decreased overall survival (OS) in both the s‐cAS and dn‐cAS groups.ConclusionApparent increase in the number of s‐cAS patients requires further attention. Surgery is still recommended for the treatment of both s‐cAS and dn‐cAS patients, and the requirement for treatment improvement is imperative.